

12 June 2024

Completion of Security Consolidation

Melodiol Global Health Limited (ASX:ME1) ('Melodiol' or 'the Company') advises that following shareholder approval at the Annual General Meeting held on 31 May 2024, the consolidation of the issued capital of the Company on the basis of 1 security for every 30 securities is now complete.

The post-consolidation securities on issue are as follows:

Security Code	Security Name	Balance
ME1	ORDINARY FULLY PAID SHARES	36,449,783
ME1O	LISTED OPT EXP 2/11/2024 @ \$150.00	1,311,484
ME1OD	LISTED OPT EXP 31/01/2027 @ \$48.00	2,218,445
ME1OE	LISTED OPT EXP 13/11/2028 @ \$3.60	1,879,158
ME1OPT33	UNL OPT EXP 23/12/2025 @ \$23.40	50,000
ME1OPT38	UNL OPT EXP 14/07/2024 @ \$228.00	20,000
ME1OPT39	UNL OPT EXP 01/08/2024 @ \$90.00	20,000
ME1OPT40	UNL OPT EXP 01/08/2024 @ \$108.00	20,000
ME1OPT41	UNL OPT EXP 06/09/2024 @ \$108.00	16,667
ME1OPT42	UNL OPT EXP 06/09/2024 @ \$150.00	16,667
ME1OPT43	UNL OPT EXP 25/10/2024 @ \$82.50	1,668
ME1OPT48	UNL OPT EXP 28/06/2024 @ \$240.00	1,044
ME1OPT49	UNL OPT EXP 28/06/2024 @ \$804.00	1,044
ME1OPT50	UNL OPT EXP 28/06/2024 @ \$1,200.00	1,044
ME1OPT51	UNL OPT EXP 28/06/2024 @ \$1,590.00	1,044
ME1OPT52	UNL OPT EXP 28/06/2025 @ \$12.00	2,748
ME1OPT54	UNL OPT EXP 24/08/2024 @ \$18.00	431,816
ME1OPT55	UNL OPT EXP 10/10/2024 @ \$24.00	3,334
ME1OPT57	UNL OPT EXP 16/11/2027 @\$13.20	17,759
ME1OPT58	UNL OPT EXP 30/11/2024 @ \$24.00	5,000
ME1PERR45	PERFORMANCE RIGHTS EXP 27/07/2025	834
ME1PERR46	PERFORMANCE RIGHTS EXP 27/07/2026	834
ME1PERR47	PERFORMANCE RIGHTS EXP 27/07/2027	1,667
ME1PERR48	PERFORMANCE RIGHTS EXP 14/07/2025	834
ME1PERR49	PERFORMANCE RIGHTS EXP 14/07/2026	834
ME1PERR50	PERFORMANCE RIGHTS EXP 14/07/2027	1,667
ME1PERR52	PERFORMANCE RIGHTS EXP 27/10/2028	83,334
ME1PERR54	PERFORMANCE RIGHTS EXP 27/10/2028	50,000
ME1PERS2	PERFORMANCE SHARES EXP 25/10/2024	5,000
ME1PERS3	PERFORMANCE SHARES EXP 25/10/2026	5,000
ME1CON7	CONVERTIBLE NOTES	584
ME1CON8	CONVERTIBLE NOTES	284

-Ends-

Authority and Contact Details

This announcement has been authorised for release by the Company Secretary.

For further information, please contact:

Investor Enquiries

Melodiol Global Health Limited

E: info@cresopharma.com

P: +61 (0) 497 571 532

About Melodiol

Melodiol Global Health Limited (ASX:ME1) brings the best of cannabis and other plant-based products to better the lives of people and animals. Melodiol strives for the highest quality in its products. It develops cannabis, hemp-derived and other plant based therapeutic, nutraceutical, and lifestyle products with wide consumer reach.

To learn more please visit: <https://melodiolglobalhealth.com/>

Melodiol offices:

Australia: Suite 5 CPC, 145 Stirling Hwy, Nedlands, WA, 6009

Canada: 59 Payzant Drive, Windsor, Nova Scotia, B0N 2T0 and 50 Ivey Ln, Windsor, Nova Scotia, B0N 2T0